Alcestobart

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug NameAlcestobart
Drug Alias NameLBL-007
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionLymphocyte activation gene 3 protein inhibitors
TargetsLymphocyte activation gene 3 protein
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[18] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesLeads Biolabs Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing Leadsbiolabs Co LtdBeigene Guangzhou Biologics Manufacturing Co LtdLeads Biolabs Inc +[6] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[9] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A